The clinical-stage biopharma firm Oncternal Therapeutics (NSDQ:ONCT) has announced that an underwriter has agreed to purchase 16,666,667 shares of its common stock at $4.50 per share minus underwriting discounts and commissions. Oncternal expects to rake in approximately $75 million from the deal. CEL-SCI (NYSEAMERICAN: CVM), a cancer immunotherapy company, has closed an offering of one million…